[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
March 3, 2015

Fenoldopam and Acute Kidney Injury

Author Affiliations
  • 1Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, St Louis Lariboisière, Paris, France
  • 2Medical-Surgical ICU, Hôpital Nord, St Priest en Jarez, Saint-Etienne, France
  • 3Division of Intensive Care and Emergency Medicine, Medical University of Innsbruck, Innsbruck, Austria
JAMA. 2015;313(9):970-971. doi:10.1001/jama.2015.410

To the Editor The trial by Dr Bove and colleagues1 found that the renal vasodilator fenoldopam did not reverse acute kidney injury (AKI) after cardiac surgery, in contrast to previous trials and meta-analyses. The failure of this selective renal vasodilator to prevent further deterioration of AKI supports current concepts that several pathophysiological mechanisms besides renal hypoperfusion are involved in AKI associated with on-pump cardiac surgery.